Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study determined the effects of insulin versus liraglutide therapy on liver fat in patients with type 2 diabetes inadequately controlled with oral agents therapy, including metformin. RESEARCH DESIGN AND METHODS: Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks. The liver proton density fat fraction (PDFF) was measured by MRS. The mean liver PDFF, the total liver volume, and the total liver fat index were measured by MRI. The Student t test, the Fisher exact test, and repeated-measures ANOVA were used for statistical analysis. RESULTS: Insulin treatment was associated with a significant improvement in glycated hemoglobin (7.9% to 7.2% [62.5 to 55.2 mmol/mol], P = 0.005), a trend toward a decrease in MRS-PDFF (12.6% to 9.9%, P = 0.06), and a significant decrease in liver mean MRI-PDFF (13.8% to 10.6%, P = 0.005), liver volume (2,010.6 to 1,858.7 mL, P = 0.01), and the total liver fat index (304.4 vs. 209.3 % ⋅ mL, P = 0.01). Liraglutide treatment was also associated with a significant improvement in glycated hemoglobin (7.6% to 6.7% [59.8 to 50.2 mmol/mol], P < 0.001) but did not change MRS-PDFF (P = 0.80), liver mean MRI-PDFF (P = 0.15), liver volume (P = 0.30), or the total liver fat index (P = 0.39). CONCLUSIONS: The administration of insulin glargine therapy reduced the liver fat burden in patients with type 2 diabetes. However, the improvements in the liver fat fraction and glycemia control were not significantly different from those in the liraglutide group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 1×
“However, the 12-week duration of our study was sufficient to address our primary end point and was justified by the normalization of transaminases, another surrogate marker of treatment response, within this interval in a previous randomized trial evaluating the effect of a thiazolidinedione in patients with type 2 di…”
BackgroundBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405 · cited 1×
“Further, GLP-1 agonists may decrease liver fat by increasing fatty acid uptake and VLDL transport (10) and stimulating hepatic lipid b-oxidation (11,12), improving hepatic insulin sensitivity (10) while also reducing hepatic lipogenesis via activation of the AMPK pathway (13).”
BackgroundJendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272 · cited 1×
“Prior studies suggested that GLP1 receptor agonists, such as liraglutide and exenatide, would improve liver steatosis in animal models (27,28), in human case series (29), and in prospective nonrandomized trials (30,31).”
BackgroundArmstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250 · cited 2×
“Furthermore, the rate of gastrointestinal adverse effects observed in this study was similar to those reported in the literature, and the rate of patient withdrawal was similar to that observed in larger randomized clinical trials (11,37,38).”
BackgroundResultCuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226 · cited 1×
“Prior studies suggested that GLP1 receptor agonists, such as liraglutide and exenatide, would improve liver steatosis in animal models (27,28), in human case series (29), and in prospective nonrandomized trials (30,31).”
BackgroundJuurinen, L., Tiikkainen, M., Häkkinen, A.-M., Hakkarainen, A., & Yki-Järvinen, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2006 · Cited by 141 · cited 1×
“The mechanisms by which insulin therapy may reduce liver fat include inhibition of lipolysis, which may reduce free fatty acid flux to the liver (7), and decreased production of endogenous insulin passing through the liver to stimulate hepatic lipogenesis (6).”
BackgroundExenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series
Kenny, P. R., Brady, D. E., Torres, D. M., Ragozzino, L., Chalasani, N., & Harrison, S. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.363 · Cited by 106
Research works printed but not linked: 21
- Wallia, 2014, Insulin therapy for type 2 diabetes mellitus, JAMA, 311, 2315, 10.1001/jama.2014.5951 · DOI · Paper page
- Tilg, 2008, Insulin resistance, inflammation, and non-alcoholic fatty liver disease, Trends Endocrinol Metab, 19, 371, 10.1016/j.tem.2008.08.005 · DOI · Paper page
- Lingvay, 2007, Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes, J Diabetes Complications, 21, 137, 10.1016/j.jdiacomp.2007.02.005 · DOI
- Jankovic, 2012, Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus, PLoS ONE, 7, e50077, 10.1371/journal.pone.0050077 · DOI
- Shah, 2011, Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes, Diabetes Obes Metab, 13, 505, 10.1111/j.1463-1326.2011.01370.x · DOI · Paper page
- Mells, 2012, Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet, Am J Physiol Gastrointest Liver Physiol, 302, G225, 10.1152/ajpgi.00274.2011 · DOI · Paper page
- Ben-Shlomo, 2011, Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase, J Hepatol, 54, 1214, 10.1016/j.jhep.2010.09.032 · DOI · Paper page
- Reeder, 2011, Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy, J Magn Reson Imaging, 34, 729, 10.1002/jmri.22580 · DOI · Paper page
- Tang, 2013, Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis, Radiology, 267, 422, 10.1148/radiol.12120896 · DOI · Paper page
- Anderwald, 2002, Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle, Diabetes, 51, 3025, 10.2337/diabetes.51.10.3025 · DOI · Paper page
- Vanhamme, 1997, Improved method for accurate and efficient quantification of MRS data with use of prior knowledge, J Magn Reson, 129, 35, 10.1006/jmre.1997.1244 · DOI · Paper page
- Hamilton, 2011, In vivo characterization of the liver fat ¹H MR spectrum, NMR Biomed, 24, 784, 10.1002/nbm.1622 · DOI · Paper page
- Yokoo, 2011, Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T, Radiology, 258, 749, 10.1148/radiol.10100659 · DOI · Paper page
- Tang, 2014, Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis, Abdom Imaging
- Nomura, 1987, Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet, Radiology, 162, 845, 10.1148/radiology.162.3.3809503 · DOI
- Chen, 2008, Correlation between hepatic steatosis, hepatic volume, and spleen volume in live liver donors, Transplant Proc, 40, 2481, 10.1016/j.transproceed.2008.08.045 · DOI
- Shirakawa, 2012, Effects of liraglutide on β-cell-specific glucokinase-deficient neonatal mice, Endocrinology, 153, 3066, 10.1210/en.2012-1165 · DOI
- Suzuki, 2013, Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus, Intern Med, 52, 1029, 10.2169/internalmedicine.52.8961 · DOI · Paper page
- Jonker, 2013, Exercise and type 2 diabetes mellitus: changes in tissue-specific fat distribution and cardiac function, Radiology, 269, 434, 10.1148/radiol.13121631 · DOI · Paper page
- Chaudhuri, 2012, Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis, Diabetes Metab Res Rev, 28, 258, 10.1002/dmrr.1305 · DOI
- Fernández-Salazar, 2011, Percutaneous liver biopsy: patients’ point of view, Scand J Gastroenterol, 46, 727, 10.3109/00365521.2011.558112 · DOI
Cited by
Non-alcoholic fatty liver disease and diabetes
Hazlehurst, J. M., Woods, C., Marjot, T., Cobbold, J. F., & Tomlinson, J. W. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.001 · Cited by 527
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Bril, F., Barb, D., Portillo‐Sanchez, P., Biernacki, D., Lomonaco, R., Suman, A., Weber, M. H., Budd, J. T., Lupi, M. E., & Cusi, K. (2017) · Hepatology · doi:10.1002/hep.28985 · Cited by 288
Metadata
- Authors
- Tang, A., Rabasa-Lhoret, R., Castel, H., Wartelle-Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A.-S., de Guise, J., Soulez, G., & Chiasson, J.-L.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-03-26
- Volume
- 38
- Issue
- 7
- Pages
- 1339-1346
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2087484038
- Cited by
- 133
- References
- 13
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Diabète Québec
- Canadian Heads of Academic Radiology-GE Healthcare
- NSERC Discovery (107998)
- Fonds de recherche du Québec en Santé (FRQ-S) and Fondation de l'association des radiologistes du Québec. Clinical Research Scholarship to An Tang (#26993)
- J-A DeSève Research Chair to Rémi Rabasa-Lhoret
- FRQ-S National Scientist Award to Gilles Soulez
- FRQ-S Senior Scholarship to Rémi Rabasa-Lhoret
- Canada Research Chair in 3D imaging and Biomedical Engineering to Jacques de Guise
- Radiological Society of North America Research and Education Foundation (RSD1108)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.